Lakewood-Amedex Reports No Revenue, Increased Expenses, and Strategic Financing in Latest 10-Q

Lakewood-Amedex Biotherapeutics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company, which specializes in developing antimicrobial therapeutics, recorded no revenue for the period, consistent with the previous year. However, total operating expenses surged to $4.68 million, up from $1.18 million in the same quarter of 2025, primarily driven by increased research and development costs and general administrative expenses. The net loss for the six months ended June 30, 2026, was approximately $4.7 million, compared to a loss of $1.2 million for the same period in 2025.

The company’s financial position improved markedly due to strategic financing activities. Lakewood-Amedex completed a private placement of its Series C Convertible Preferred Stock on April 21, 2026, raising approximately $6.8 million in net proceeds. This financing was pivotal in enhancing the company's liquidity and allowed it to repay outstanding short-term promissory notes. Additionally, the company’s common stock began trading on the Nasdaq Capital Market on April 23, 2026, marking a significant milestone in its corporate evolution.

Operationally, Lakewood-Amedex is advancing its lead product candidate, Nu-3, a topical antimicrobial therapy for diabetic foot ulcers. The company is preparing for a Phase 2a clinical study, which has contributed to a 242% increase in research and development expenses to $503,020 for the three months ended June 30, 2026. The increase in general and administrative expenses was even more pronounced, rising 571% to $3.29 million, largely due to professional services related to the Nasdaq listing and other compliance costs.

As of June 30, 2026, Lakewood-Amedex reported total assets of approximately $4.96 million, a substantial increase from $481,598 at the end of 2025. The company’s cash and cash equivalents rose to $2.58 million, up from $236,400 at the end of the previous fiscal year. The total liabilities decreased significantly to $628,926 from $2.45 million, reflecting the conversion of preferred stock and promissory notes into common stock, which simplified the capital structure.

Looking ahead, Lakewood-Amedex anticipates that while its current capital resources will support operations into early 2027, additional financing will be necessary to complete clinical development and pursue regulatory approvals. The company is exploring various financing options, including equity financings and strategic partnerships, to support its long-term objectives. Management remains focused on executing its clinical development strategy while addressing the ongoing need for capital to sustain operations.